Applied StemCell Revenue and Competitors

Location

$23.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Applied StemCell's estimated annual revenue is currently $3.4M per year.(i)
  • Applied StemCell received $19.0M in venture funding in June 2016.
  • Applied StemCell's estimated revenue per employee is $77,500
  • Applied StemCell's total funding is $23.5M.

Employee Data

  • Applied StemCell has 44 Employees.(i)
  • Applied StemCell grew their employee count by 0% last year.

Applied StemCell's People

NameTitleEmail/Phone
1
FounderReveal Email/Phone
2
Co-founderReveal Email/Phone
3
CEO and PresidentReveal Email/Phone
4
SVP, Scientific AlliancesReveal Email/Phone
5
Head Research and DevelopmentReveal Email/Phone
6
Head GMP and QualityReveal Email/Phone
7
Senior Director, MarketingReveal Email/Phone
8
Director Technical OperationsReveal Email/Phone
9
Associate Director Technical Operations & Project ManagementReveal Email/Phone
10
Director Genome Technology CoreReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Applied StemCell?

Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California. Our goal is to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry. After years of research and development, ASC is proud to offer an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications. We are currently focusing on three areas: (1) cell line generation for bio-production and bioassays (2) patient-relevant cell models for personalized medicine and (3) physiologically predictive animal models of human diseases. We are striving to improve and expand our technologies and product lines to meet the increasing requirements of the biomedical community. ASC welcomes your comments, suggestions and ideas. Establishing cell models Establishing disease-specific isogenic models Developing master cell lines for antibody/protein production Generating iPSCs from patients containing the corrected mutations or inserted genes for pre-clinical applications Generating animal models (mouse/rat models) Using our TARGATT technology, a gene-of-interest can be specifically inserted at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression. This site-specific Knock-in technology has been first established in mouse models, and we have successfully applied it to human cell lines. We are moving forward to various projects that will combine the CRISPR/Cas9 technology and TARGATT for highly specified transgene expression. For patent licensing, business development, and investment inquiries, please contact us at info@appliedstemcell.com.

keywords:Biotechnology,E-Commerce,Healthcare,Pharmaceuticals

$23.5M

Total Funding

44

Number of Employees

$3.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Applied StemCell News

2022-04-20 - In Brief This Week: Biocartis, Co-Diagnostics, Blueprint ...

Applied Cells and Stemcell Technologies Canada said this week that they are collaborating to develop a high-performance cell separation...

2022-04-17 - Applied Cells Enters into a Supply Agreement with ...

"The combined solutions of the Applied Cells MARS platform and STEMCELL Technologies' cell separation reagents bring to the research market a...

2022-04-17 - Applied Cells signs deal with Stemcell for cell separation kits

April 20, 2022 -- Applied Cells and Stemcell Technologies are collaborating to combine Applied Cells' Multiphysics Automated Reconfigurable Separation...

2016-06-06 - Gene Editing Company Applied StemCell Secures $19M in Series D Financing

Applied StemCell, Inc., a Milpitas, CA-based gene-editing company, closed a $19m Series D funding round. The round was led by HerMed Capital with participation from Ping An Ventures, Vi-Ventures and BioSciKin. The company intends to use the proceeds to accelerate the development of its pipelin ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.8M44-32%$29.9M
#2
$5.2M457%N/A
#3
$7.4M4510%N/A
#4
$5M45N/AN/A
#5
$8.9M450%N/A

Applied StemCell Funding

DateAmountRoundLead InvestorsReference
2016-06-07$19.0MDHerMed CapitalArticle